Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[A new radiation-free conditioning in bone marrow transplantation and dibromo-mannitol therapy in chronic myeloid leukemia].
Kelemen E, Dénes R, Barta A, Masszi T, Reményi P, Pálóczi K, Bátai A, Torbágyo E, Sipos A, Lengyel L, Jakab K, Gyódi E, Réti M, Földi J, Páldi-Haris P, Manuel A, Fekete S, Török J, Hoffer I, Jakab J, Váradi G, Petrányi G. Kelemen E, et al. Among authors: barta a. Orv Hetil. 1998 Aug 23;139(34):2003-1; discussion 2011-2. Orv Hetil. 1998. PMID: 9745304 Review. Hungarian.
Immunological importance of chimerism in transplantation: new conditioning protocol in BMT and the development of chimeric state.
Barta A, Bátai A, Kelemen E, Lengyel L, Reményi P, Sipos A, Torbágyi E, Avalos M, Fekete E, Földi J, Páldi-Haris P, Tamáska J, Gyódi E, Rajczy K, Hoffer I, Jakab J, Petrányi GG, Pálóczi K. Barta A, et al. Hum Immunol. 2000 Feb;61(2):101-10. doi: 10.1016/s0198-8859(99)00143-3. Hum Immunol. 2000. PMID: 10717801 Review.
Remarkably reduced transplant-related complications by dibromomannitol non-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia.
Barta A, Dénes R, Masszi T, Reményi P, Bátai A, Torbágyi E, Sipos A, Lengyel L, Jakab K, Gyódi E, Réti M, Földi J, Páldi-Haris P, Avalos M, Pálóczi K, Fekete S, Török J, Hoffer I, Jakab J, Váradi G, Kelemen E, Petrányi G. Barta A, et al. Acta Haematol. 2001;105(2):64-70. doi: 10.1159/000046536. Acta Haematol. 2001. PMID: 11408706 Clinical Trial.
Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N, Kozma A, Halm G, Nahajevszky S, Bátai A, Fekete S, Barta A, Ujj G, Lueff S, Sipos A, Adám E, Bors A, Reményi P, Masszi T, Tordai A, Andrikovics H. Meggyesi N, et al. Among authors: barta a. Acta Haematol. 2012;127(1):34-42. doi: 10.1159/000331472. Epub 2011 Oct 14. Acta Haematol. 2012. PMID: 22005133
224 results